Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in adolescents with paroxysmal nocturnal hemoglobinuria
NL-OMON59702Phase 2Not yet recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Apr 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Primary endpoints: Pegcetacoplan pharmacokinetics over 16 weeks, Change in hemoglobin and 3 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON59702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59702.